ARO-C3 Market Summary

Key Factors Driving ARO-C3 Growth

1. Strong Early Clinical Efficacy in IgA Nephropathy (IgAN)

ARO-C3 has generated encouraging Phase I/II data in patients with IgAN, a chronic kidney disease with significant unmet need.

In March 2025, Arrowhead reported:

o Mean sustained reductions in C3 levels of ≥87%

o Mean reductions in AH50 (alternative pathway activity) of ≥76%

o Mean reductions in Wieslab AP activity of ≥89%

o Mean reduction in urine protein-to-creatinine ratio (UPCR) of 41% by Week 24

Proteinuria reduction is considered a clinically meaningful surrogate endpoint in IgAN and is often associated with improved long-term renal outcomes.

2. Large Unmet Need in Complement-Mediated Kidney Diseases

Arrowhead is positioning ARO-C3 for multiple complement-driven renal disorders including:

o IgA nephropathy (IgAN)

o C3 glomerulopathy (C3G)

o Potentially paroxysmal nocturnal hemoglobinuria (PNH) and other complement disorders

The company has repeatedly highlighted that substantial unmet need remains despite the availability of C5 inhibitors because many patients continue progressing toward renal impairment. IgAN alone is among the most common primary glomerular diseases worldwide and carries significant risk of progression to end-stage renal disease.

3. Differentiated Upstream Complement Inhibition Strategy

Unlike approved C5 inhibitors that block the terminal complement cascade, ARO-C3 targets complement component C3 upstream, potentially enabling broader suppression of complement activation.

Arrowhead believes upstream C3 inhibition may provide:

o More comprehensive complement pathway control

o Greater reductions in inflammatory kidney injury

o Potential efficacy across multiple complement-mediated diseases

4. Durable RNAi Mechanism Supports Infrequent Dosing

One of the major commercial advantages of Arrowhead’s RNAi platform is durable target suppression with infrequent administration.

Phase I/II data demonstrated pharmacologic activity supportive of:

o Quarterly or less frequent subcutaneous dosing

Less frequent dosing may improve:

o Patient adherence

o Convenience

o Physician adoption

o Long-term treatment persistence

compared with chronic infusion-based complement therapies.

5. Favorable Early Safety and Tolerability Profile

Early clinical results showed encouraging tolerability:

o No serious or severe treatment-emergent adverse events

o No discontinuations due to adverse events

o No infections with encapsulated organisms reported in IgAN patients

Safety is especially important for complement-targeted therapies because broad complement suppression can increase infection risk. Early tolerability data therefore strengthens confidence in continued development.

ARO-C3 Recent Developments

Arrowhead Pharmaceuticals announced that it has dosed the first subjects in AROC3-1001, a Phase I/II clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases.

“ARO-C3 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of ARO-C3 for potential indication like IgA nephropathy, and Membranoproliferative glomerulonephritis in the 7MM. A detailed picture of ARO-C3’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the ARO-C3 for potential indications. The ARO-C3 market report provides insights about ARO-C3’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current ARO-C3 performance, future market assessments inclusive of the ARO-C3 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of ARO-C3 sales forecasts, along with factors driving its market.

ARO-C3 Drug Summary

ARO-C3 is an investigational RNA interference (RNAi) therapeutic being developed by Arrowhead Pharmaceuticals for the treatment of complement-mediated renal diseases, particularly conditions driven by dysregulation of the complement cascade such as C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis. The therapy utilizes Arrowhead’s proprietary TRiM platform to selectively silence hepatic production of complement component 3 (C3) messenger RNA, thereby reducing circulating C3 protein levels and limiting downstream complement activation implicated in kidney inflammation and tissue damage. Administered subcutaneously, ARO-C3 is designed to provide sustained target suppression with infrequent dosing, potentially offering a convenient alternative to chronic complement inhibitor therapies. Preclinical and early clinical studies have demonstrated robust and durable reductions in serum C3 levels, supporting its potential utility in rare kidney diseases characterized by uncontrolled complement activation. As an investigational therapy, its safety and efficacy continue to be evaluated, with current studies monitoring adverse events, infection risk related to complement suppression, and long-term renal outcomes in treated patients. The report provides ARO-C3’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the ARO-C3 Market Report

The report provides insights into:

• A comprehensive product overview including the ARO-C3 MoA, description, dosage and administration, research and development activities in potential indication like IgA nephropathy, and Membranoproliferative glomerulonephritis.
• Elaborated details on ARO-C3 regulatory milestones and other development activities have been provided in ARO-C3 market report.
• The report also highlights ARO-C3‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The ARO-C3 market report also covers the patents information, generic entry and impact on cost cut.
• The ARO-C3 market report contains current and forecasted ARO-C3 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The ARO-C3 market report also features the SWOT analysis with analyst views for ARO-C3 in potential indications.

Methodology

The ARO-C3 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ARO-C3 Analytical Perspective by DelveInsight

• In-depth ARO-C3 Market Assessment

This ARO-C3 sales market forecast report provides a detailed market assessment of ARO-C3 for potential indication like IgA nephropathy, and Membranoproliferative glomerulonephritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted ARO-C3 sales data uptil 2034.

• ARO-C3 Clinical Assessment

The ARO-C3 market report provides the clinical trials information of ARO-C3 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

ARO-C3 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

ARO-C3 Market Potential & Revenue Forecast

• Projected market size for the ARO-C3 and its key indications
• Estimated ARO-C3 sales potential (ARO-C3 peak sales forecasts)
• ARO-C3 Pricing strategies and reimbursement landscape

ARO-C3 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• ARO-C3 Market positioning compared to existing treatments
• ARO-C3 Strengths & weaknesses relative to competitors

ARO-C3 Regulatory & Commercial Milestones

• ARO-C3 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

ARO-C3 Clinical Differentiation

• ARO-C3 Efficacy & safety advantages over existing drugs
• ARO-C3 Unique selling points

ARO-C3 Market Report Highlights

• In the coming years, the ARO-C3 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The ARO-C3 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ARO-C3’s dominance.
• Other emerging products for IgA nephropathy, and Membranoproliferative glomerulonephritis are expected to give tough market competition to ARO-C3 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ARO-C3 in potential indications.
• Analyse ARO-C3 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted ARO-C3 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of ARO-C3 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of ARO-C3? How strong is ARO-C3’s clinical and commercial performance?
• What is ARO-C3’s clinical trial status in each individual indications such as IgA nephropathy, and Membranoproliferative glomerulonephritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ARO-C3 Manufacturers?
• What are the key designations that have been granted to ARO-C3 for potential indications? How are they going to impact ARO-C3’s penetration in various geographies?
• What is the current and forecasted ARO-C3 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of ARO-C3 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ARO-C3 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is ARO-C3? What is the duration of therapy and what are the geographical variations in cost per patient?